Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/167936
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCánovas, Verónica-
dc.contributor.authorPuñal, Yolanda-
dc.contributor.authorMaggio, Valentina-
dc.contributor.authorRedondo, Enric-
dc.contributor.authorMarín Aguilera, Mercedes-
dc.contributor.authorMellado González, Begoña-
dc.contributor.authorOlivan Riera, Mireia-
dc.contributor.authorLleonart, Matilde E.-
dc.contributor.authorPlanas, Jacques-
dc.contributor.authorMorote, Juan-
dc.contributor.authorPaciucci Barzanti, Rosanna-
dc.date.accessioned2020-07-07T09:57:09Z-
dc.date.available2020-07-07T09:57:09Z-
dc.date.issued2017-07-22-
dc.identifier.issn1949-2553-
dc.identifier.urihttp://hdl.handle.net/2445/167936-
dc.description.abstractMetastatic prostate cancer is presently incurable. The oncogenic protein PTOV1, first described in prostate cancer, was reported as overexpressed and significantly correlated with poor survival in numerous tumors. Here, we investigated the role of PTOV1 in prostate cancer survival to docetaxel and self-renewal ability. Transduction of PTOV1 in docetaxel-sensitive Du145 and PC3 cells significantly increased cell survival after docetaxel exposure and induced docetaxel-resistance genes expression (ABCB1, CCNG2 and TUBB2B). In addition, PTOV1 induced prostatospheres formation and self-renewal genes expression (ALDH1A1, LIN28A, MYC and NANOG). In contrast, Du145 and PC3 cells knockdown for PTOV1 significantly accumulated in the G2/M phase, presented a concomitant increased subG1 peak, and cell death by apoptosis. These effects were enhanced in docetaxel-resistant cells. Analyses of tumor datasets show that PTOV1 expression significantly correlated with prostate tumor grade, drug resistance (CCNG2) and self-renewal (ALDH1A1, MYC) markers. These genes are concurrently overexpressed in most metastatic lesions. Metastases also show PTOV1 genomic amplification in significant co-occurrence with docetaxel-resistance and self-renewal genes. Our findings identify PTOV1 as a promoter of docetaxel-resistance and self-renewal characteristics for castration resistant prostate cancer. The concomitant increased expression of PTOV1, ALDH1A1 and CCNG2 in primary tumors, may predict metastasis and bad prognosis.-
dc.format.extent16 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherImpact Journals-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.18632/oncotarget.19467-
dc.relation.ispartofOncotarget, 2017, vol. 8, num. 35, p. 59165-59180-
dc.relation.urihttps://doi.org/10.18632/oncotarget.19467-
dc.rightscc-by (c) Cánovas, Verónica et al., 2017-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.subject.classificationApoptosi-
dc.subject.classificationMetàstasi-
dc.subject.classificationCàncer de pròstata-
dc.subject.otherApoptosis-
dc.subject.otherMetastasis-
dc.subject.otherProstate cancer-
dc.titleProstate tumor overexpressed-1 (PTOV1) promotes docetaxel- resistance and survival of castration resistant prostate cancer cells-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec697750-
dc.date.updated2020-07-07T09:57:10Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
697750.pdf5.98 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons